CRSP / CRISPR Therapeutics AG - Документы SEC, Годовой отчет, Доверенное заявление

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results -CASGEVY®momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collecte

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results -CASGEVY®momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- -Clinical trial ongoing for CTX310™, targeting ANGPTL3, with prel

Collaboration, Option and License Agreement, dated May 19, 2025, by and between CRISPR Therapeutics AG, Sirius Therapeutics and Sirius Therapeutics, Inc.

Exhibit 10.1 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. EXECUTION VERSION COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN SIRIUS THERAPEUTICS AND S

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 C

FORM 8-K Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 CRISPR THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

Amended and Restated Articles of Association of CRISPR Therapeutics AG

Exhibit 3.1 Articles of association STATUTEN of der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in mit Sitz in Zug Zug (Translation; in case of controversy the German text shall prevail) I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

Calculation of Filing Fee Table (Form Type) CRISPR Therapeutics AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) CRISPR Therapeutics AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(1) Newly Registered Securities Fees to Be Paid Equity Common Shares, CHF 0.

Common Shares

Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-281262 PROSPECTUS SUPPLEMENT (To prospectus dated August 5, 2024) 1,842,105 Common Shares We are offering an aggregate of 1,842,105 of our common shares, or the Shares, directly to Sirius Therapeutics, or Sirius, pursuant to a Share Issuance Agreement, dated May 19, 2025, or the Share Issuance Agreement, in connection with a C

Form of Share Issuance Agreement

Exhibit 10.1 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Final Form SHARE ISSUANCE AGREEMENT This SHARE ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of [●], by and among CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incor

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglyceri

Exhibit 99.1 CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety pro

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Exhibit 99.1 CRISPR Therapeutics Announces Transition of Chief Operating Officer ZUG, Switzerland and BOSTON, March 26, 2025 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi

Description of Capital Shares.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 11, 2025, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and does not purport to be complete

CRISPR Therapeutics AG Insider Trading Policy.

Exhibit 19.1 CRISPR THERAPEUTICS AG INSIDER TRADING POLICY (As amended on September 12, 2024) CRISPR Therapeutics AG (together with its subsidiaries, the “Company” or “we” or “us”) has adopted the following policy and procedures for trading in the Company’s securities (“Insider Trading Policy”). It is designed to prevent the misuse of material nonpublic information, insider trading in securities,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co

CRISPR Therapeutics AG Organizational Rules

Exhibit 10.35 ORGANIZATIONAL RULES OF CRISPR THERAPEUTICS AG (ORGANISATIONSREGLEMENT) 1. BASIS AND ORGANIZATION 2 2. GENERAL PROVISIONS 2 3. BOARD OF DIRECTORS 4 4. CHAIRPERSON 9 5. CEO 9 6. EXECUTIVE COMMITTEE 10 7. COMPENSATION COMMITTEE 11 8. NOMINATION AND CORPORATE GOVERNANCE COMMITTEE 12 9. AUDIT COMMITTEE 12 10. INDEMNIFICATION 12 11. FINAL PROVISIONS 13 1. BASIS AND ORGANIZATION 1.1 Basis

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results -2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum;

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results -2025 is poised to be a catalyst-rich year with key updates across several programs- -Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activat

CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm2430446d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* CRISPR Therapeutics AG (Name of Issuer) Common stock (Title of Class of Securities) H17182108 (CUSIP Number) November 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) i

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had c

Form of Indemnification Agreement

Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of by and between CRISPR Therapeutics AG, a Swiss stock corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in order to induce Indemnitee to provide or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPE

As filed with the Securities and Exchange Commission on August 5, 2024

Table of Contents As filed with the Securities and Exchange Commission on August 5, 2024 Registration No.

Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables S-3 CRISPR Therapeutics AG Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Shares, CHF 0.

Employment Agreement, dated May 28, 2024, by and between CRISPR Therapeutics, Inc. and Naimish Patel, M.D.

Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 28th day of May, 2024 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Naimish Patel (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full executi

Form of Subordinated Debt Indenture between the Registrant and one or more trustees to be named

Exhibit 4.2 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUTICS

Filing Fee Table

Exhibit 107 Calculation of Registration Fee CRISPR Therapeutics AG (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered (Form S-8) Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2018 Stock Option and Incentive Plan 457(h) 1,000,000 $56.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi

Form of Senior Debt Indenture between the Registrant and one or more trustees to be named

Exhibit 4.1 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se

As filed with the Securities and Exchange Commission on August 5, 2024

As filed with the Securities and Exchange Commission on August 5, 2024 Registration No.

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 CRISPR THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

Amended and Restated Articles of Association of CRISPR Therapeutics AG

Articles of association STATUTEN of der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in mit Sitz in Zug Zug (Translation; in case of controversy the German text shall prevail) I.

Employment Agreement, dated May 23, 2024, by and between CRISPR Therapeutics, Inc. and Julianne Bruno

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 23rd day of May, 2024 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Julianne Bruno (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full execut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEU

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results — More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected— —Clinical trials

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results — More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected— —Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indicatio

CRSP / CRISPR Therapeutics AG / Capital International Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) March 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 16, 2024, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and does not purport to be complete

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co

CRISPR Therapeutics AG Policy Relating to Recovery of Erroneously Awarded Compensation

Exhibit 97.1 CRISPR THERAPEUTICS AG COMPENSATION RECOVERY POLICY Adopted as of October 12, 2023 CRISPR Therapeutics AG (the “Company”) has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company or any of its subsidiaries shall recover Erroneously Awarded Compensation from Covered Persons

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively – — Clinical trials ongoing for in vivo ge

Calculation of Filing Fee Table (Form Type) CRISPR Therapeutics AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security  Type  Security Class Title Fee Calculation or Carry Forward Rule Amount Registere

Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) CRISPR Therapeutics AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security  Type  Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(1) Newly Registered Securities Fees to Be Paid Equity Common Shares, CHF 0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 CRISPR THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Form of Investment Agreement

EX-10.1 Exhibit 10.1 INVESTMENT AGREEMENT This INVESTMENT AGREEMENT (this “Agreement”) is made and entered into as of February 13, 2024, by and among CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 CRISPR THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

3,916,082 Common Shares

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258274 Prospectus Supplement (To prospectus dated July 29, 2021) 3,916,082 Common Shares We are offering 3,916,082 common shares, in a registered direct offering to a limited number of purchasers pursuant to this prospectus supplement and the accompanying prospectus. The issue price of each common share equals $71.50 Our commo

CRSP / CRISPR Therapeutics AG / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul

CRSP / CRISPR Therapeutics AG / Capital International Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

CRSP / CRISPR Therapeutics AG / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 4 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r

CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm244117d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* CRISPR Therapeutics AG (Name of Issuer) Common stock (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Amendment No. 1 to the Amended and Restated Joint Development and Commercialization Agreement, dated December 12, 2023, by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited, and on the other hand, CRISPR Therapeutics AG, CRISPR Therapeutics Limited,

[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THER

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results -Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results -Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of severe sickle cell disease (SCD) completed October 31, 2023; exa-cel assigned Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2023 for SCD- -Exa-cel assigned PDUFA target action da

CRISPR Therapeutics Announces Leadership Transition -CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023- -Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continu

Exhibit 99.1 CRISPR Therapeutics Announces Leadership Transition -CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023- -Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue serving as CEO of the Company- ZUG, Switzerland and Boston, Mass., September 7, 2023 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on August 7, 2023

As filed with the Securities and Exchange Commission on August 7, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Registration Fee CRISPR Therapeutics AG (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered (Form S-8) Security Type Security Class Title Fee Calculation Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, CHF 0.

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent B

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results -FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for SCD and Standard Review for TDT- -PDUFA target action date of December 8, 2023, for SCD and Ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

Amended and Restated Articles of Association (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 9, 2023).

Exhibit 3.1 Articles of association STATUTEN of der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in mit Sitz in Zug Zug (Translation; in case of controversy the German text shall prevail) I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress - Both trials met the primary and key secondary endp

Exhibit 99.2 Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress - Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consis

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by FDA - - FDA grants Priority R

Exhibit 99.1 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia - First CRISPR gene-editing filings to be accepted for review by FDA - - - FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) - - PDUFA target action

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 CRISPR THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEU

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)- -EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and He

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -EU and UK filings completed in 2022; su

Exhibit 99.1 Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- BOSTON and ZUG, Switzerland, April 3, 2023 - V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi

CRISPR Therapeutics Announces Departure of Board Member

Exhibit 99.1 CRISPR Therapeutics Announces Departure of Board Member ZUG, Switzerland and Boston, Mass., March 29, 2023 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Director

Non-Exclusive License Agreement, dated March 23, 2023, by and between Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 27, 2023).

Exhibit 10.1 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED AND CRISPR THERAPEU

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes -Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate

Exhibit 99.1 Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes -Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- -CRISPR Therapeutics to receive $100M upfront payment plus milestone and roy

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Exhibit 99.1 CRISPR Therapeutics Announces Transition of Chief Financial Officer ZUG, Switzerland and Boston, Mass., March 13, 2023 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

Employment Agreement, dated March 14, 2023, by and between CRISPR Therapeutics, Inc. and Raju Prasad, Ph.D. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 14, 2023).

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made as of the 14th day of March, 2023 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Raju Prasad (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full executi

Description of Capital Shares

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 21, 2023, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and does not purport to be complete

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results -Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing Application (BLA) submission on track for completion by end of Q1 2023- -Enrollment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Co

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU

CRSP / Crispr Therapeutics AG / Capital International Investors - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

CRSP / Crispr Therapeutics AG / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul

CRSP / Crispr Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

CRSP / Crispr Therapeutics AG / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 3 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, nominal value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Com

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results -Exagamglogene autotemcel (exa-cel), formerly known as CTX001™ submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begi

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results -Exagamglogene autotemcel (exa-cel), formerly known as CTX001™ submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S. submission package expected in Q1 2023; EMA and MHRA submissions are on track for Q4 2022- -En

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THER

CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer

Exhibit 99.1 CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer ZUG, Switzerland and BOSTON, Mass. – October 27, 2022 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Lawrence Klein, Ph.D., will be stepping down from the Company t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submi

Exhibit 99.1 Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 ? - EMA and MHRA submissions are on track for Q4 2022 ? - Exa-cel granted Fast Track, Regenerative Medicine Adva

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (C

As filed with the Securities and Exchange Commission on August 8, 2022

As filed with the Securities and Exchange Commission on August 8, 2022 Registration No.

Lease Commencement Date Agreement, dated May 1, 2022, by and between CRISPR Therapeutics AG and 105 W First Street Owner, L.L.C. (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 8, 2022).

Exhibit 10.2 Lease Commencement Date Agreement THIS LEASE COMMENCEMENT DATE AGREEMENT, made as of this 1st day of May, 2022, by and between 105 W FIRST STREET OWNER, L.L.C., a Delaware limited liability company (?Landlord?), and CRISPR THERAPEUTICS, INC. (?Tenant?). WITNESSETH: THAT, WHEREAS, Landlord and Tenant have entered into that certain Lease (as amended, the?Lease?) dated as of July 24, 202

Filing Fee Table

Exhibit 107 Calculation of Registration Fee CRISPR Therapeutics AG (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered (Form S-8) Security Type Security Class Title Fee Calculation Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, CHF 0.

Employment Agreement, dated May 23, 2022, by and between CRISPR Therapeutics AG and Phuong Khanh Morrow

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 23rd day of May, 2022 between CRISPR Therapeutics, Inc., a Delaware corporation (the ?Company?), and Phuong Khanh Morrow (the ?Executive? and, together with the Company, the ?Parties? or each individually, a ?Party?). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full e

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUT

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results -CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the Europ

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results -CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); discussions with the U.S. Food and Drug Ad

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland 001-37923 Not Applicable (State or other jurisdiction of incorporation) (Commi

June 23, 2022

June 23, 2022 Ms. Vanessa Robertson Mr. Kevin Vaughn Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: CRISPR Therapeutics AG Form 10-K for the fiscal year ended December 31, 2021 Filed February 15, 2022 File No. 001-37923 Dear Ms. Robertson and Mr. Vaughn: This letter is submitted on behalf of CRISPR Therapeuti

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations

CRISPR Therapeutics Innovation Day June 21, 2022 Exhibit 99.1 The presentation and other related materials may contain a number of ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics? expectations about any or all of the following: (i) its plans and expectations for its preclinical s

Amended and Restated Articles of Association (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 13, 2022).

Exhibit 3.1 Articles of association of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress -70% overall response rate (ORR) and 30% complete res

Exhibit 99.2 CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT?-LYM Trial of CTX130? in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress -70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benef

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress - Data from 75 patients with transfusion-dependent beta

Exhibit 99.1 Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress - Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to b

Disclosures The COBALT™ – LYM study of CTX130TM is sponsored by CRISPR Therapeutics Dr. Swaminathan P. Iyer is a Professor, Lead of the T Cell Lymphoma Program, Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD

THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES Swaminathan P.

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

Exhibit 99.1 CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

Exhibit 99.1 CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130? for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress ZUG, Switzerland and CAMBRIDGE, Mass. ? May 12, 2022 - (GLOBE NEWSWIRE) - CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transfo

Abstract Submission

Exhibit 99.2 Abstract Submission 25. Gene therapy, cellular immunotherapy and vaccination - Clinical EHA-1957 THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9?ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T-CELL MALIGNANCIES Swaminathan P. Iyer* 1, R. Alejandro Sica2, P. Joy Ho3, Boyu Hu4, Jasmine Zain5, Anca Prica6, Wen-Ka

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEU

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commissi

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results - More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -I

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results - More than 75 patients dosed with CTX001? across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110?, targe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 crsp-defa14a-2022.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a

Amendment No.3 to the 2018 Stock Option and Incentive Plan (incorporated herein by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A filed on April 25, 2022).

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

Letter Agreement dated January 6, 2022, by and between CRISPR Therapeutics, Inc. and 105 W First Street Owner, L.L.C. (incorporated herein by reference to Exhibit 10.37 to the Company’s Annual Report on Form 10-K filed on February 15, 2022).

Exhibit 10.37 105 W. First Street Owner, L.L.C. c/o Breakthrough Spaces, L.L.C. Tishman Speyer 45 Rockefeller Plaza New York, New York 10111 January 6, 2022 CRISPR Therapeutics, Inc. 610 Main Street North Cambridge, Massachusetts 02139 Attn: Brendan Smith, Chief Financial Officer RE: Lease (the ?Lease?) dated as of July 24, 2020, between 105 W. First Street Owner, L.L.C. (the ?Landlord?) and CRISP

Letter Agreement dated December 16, 2021 by and between CRISPR Therapeutics, Inc. and Pfizer Inc.

Exhibit 10.32 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. December 16, 2021 Via Overnight Courier Service CRISPR Therapeutics, Inc. 610 Main Street Cambridge, MA 02139 and 200 Sidney Road Cambridge, MA 02142 Re: 610 Main Street, 5th, 6th and 7th Floors, Cambrid

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - More than 70 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory subm

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results - More than 70 patients have been dosed with CTX001? across CLIMB-Thal-111 and CLIMB-SCD-121 to date; enrollment complete and regulatory submissions planned for late 2022- -Initiated and began dosing patients in the pivotal trial of CTX110?, targeting CD19+ B-cell malignancies;

Description of Capital Shares

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 15, 2022, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). The following description of our common shares is a summary and does not purport to be complete

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware CRISPR Therapeutics Ltd. United Kingdom TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts Casebia Therapeutics Limited Liability Partnership United Kingdom Casebia Therapeutics LLC Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU

CRSP / Crispr Therapeutics AG / Nikko Asset Management Americas, Inc. - SC13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

CRSP / Crispr Therapeutics AG / Capital International Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

CRSP / Crispr Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

CRSP / Crispr Therapeutics AG / Sumitomo Mitsui Trust Holdings, Inc. - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

Exhibit 99.1 CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110? for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies ZUG, Switzerland and CAMBRIDGE, Mass., November 22, 2021 ? CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results -Achieved target enrollment in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022- -Reported positive results from the ongoing Phase 1 CARBON clinical trial evaluating the safety and efficacy of CTX110? for CD19+ B-cel

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THER

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Exhibit 99.1 CRISPR Therapeutics Announces Transition of Chief Financial Officer ZUG, Switzerland and CAMBRIDGE, Mass. ? October 14, 2021 ? (GLOBE NEWSWIRE) ? CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. S

Employment Agreement, dated October 14, 2021, by and between CRISPR Therapeutics, Inc. and Brendan Smith (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 14, 2021).

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made as of the 14th day of October, 2021 between CRISPR Therapeutics, Inc., a Delaware corporation (the ?Company?), and Brendan Smith (the ?Executive? and, together with the Company, the ?Parties? or each individually, a ?Party?). WHEREAS, this Employment Agreement shall become effective upon the later of the (i) full exe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations

Updated Results from the Phase 1 CARBON Trial of CTX110? October 12, 2021 ? Exhibit 99.

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a sing

EX-99.1 Exhibit 99.1 CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies -58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in LBCL achieved with six

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

CRSP / Crispr Therapeutics AG / ARK Investment Management LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

CRSP / Crispr Therapeutics AG / Capital International Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEUT

Second Amendment to Lease dated April __, 2021, by and between CRISPR Therapeutics, Inc. and 33 NYA OWNER (DE) LLC, as successor in interest to CRP/KING 33 NY AVE. OWNER, L.L.C. (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on July 29, 2021).

Exhibit 10.1 33 New York Avenue Framingham, MA Second Amendment to Lease CRISPR Therapeutics, Inc. THIS SECOND AMENDMENT TO LEASE (?Second Amendment?) is made as of April , 2021 (the ?Effective Date?) by and between 33 NYA OWNER (DE) LLC, a Delaware limited liability company (?Landlord?), and CRISPR THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Background Pursuant to the provisions of tha

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

Consent of Goodwin Procter LLP (included in Exhibit 5.3)

Exhibit 5.3 July 29, 2021 CRISPR Therapeutics AG Baarerstrasse 14 6300 Zug Switzerland Re: Securities Being Registered under Registration Statement on Form S-3 We have acted as U.S. counsel to you in connection with your filing of an automatic shelf registration statement on Form S-3 (as amended or supplemented, the ?Registration Statement?) pursuant to the Securities Act of 1933, as amended (the

Form of Subordinated Debt Indenture between the Registrant and one or more trustees to be named

EX-4.2 3 d174706dex42.htm EX-4.2 Exhibit 4.2 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Se

Letter Agreement dated April 29, 2021 by and between CRISPR Therapeutics, Inc. and Pfizer Inc.

Exhibit 10.2 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. April 29, 2021 VIA E-MAIL Pfizer Inc. Legal Division 235 East 42nd Street New York, NY 10017 Attention: William C. Longa Re: Sublease dated August 1, 2016 (?5th Floor Sublease?) between Pfizer Inc. (?Pfiz

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected i

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results - More than 45 patients have been dosed with CTX001? across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021- -Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX130? for the treatment of T-cell lymphoma- -Enrollment o

Form of Senior Debt Indenture between the Registrant and one or more trustees to be named

Exhibit 4.1 CRISPR THERAPEUTICS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?] Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Se

As filed with the Securities and Exchange Commission on July 29, 2021

Table of Contents As filed with the Securities and Exchange Commission on July 29, 2021 Registration No.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

Amended and Restated Articles of Association of CRISPR Therapeutics AG

Exhibit 3.1 Articles of association of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I. Corporate Name, Principal Office, Duration and Purpose of the Company I. Firma, Sit

Poster presentation: CTX001™ for Sickle Cell Disease: Safety and Efficacy Results from the Ongoing CLIMB SCD-121 Study of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells, dated June 11, 2021

Connecting Hematology For Clinical and Research Excellence VIRTUAL June 9 - 17, 2021 EHA 2021 CTX001? for Sickle Cell Disease: Safety and Efficacy Results from the Ongoing CLIMB SCD-121 Study of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells S.

Poster presentation: CTX001™ for Transfusion-Dependent β-Thalassemia: Safety and Efficacy Results from the Ongoing CLIMB THAL-111 Study of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells, dated June 11, 2021

Connecting Hematology For Clinical and Research Excellence VIRTUAL June 9 - 17, 2021 EHA 2021 CTX001? for Transfusion-Dependent ?-Thalassemia: Safety and Efficacy Results from the Ongoing CLIMB THAL-111 Study of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells F.

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting - Beta thalassemia: Al

Exhibit 99.1 Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001? at European Hematology Association Annual Meeting - Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commiss

- DEFA14A

DEFA14A 1 crsp-defa14a20210610.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

definitive proxy statement

DEF 14A 1 crsp-def14a20210610.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results - Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)- -More than 30 patien

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results - Granted Priority Medicines designation by the European Medicines Agency for CTX001? for transfusion-dependent beta thalassemia (TDT)- -More than 30 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 20

Amended and Restated Joint Development and Commercialization Agreement between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited, and on the other hand, CRISPR Therapeutics AG, CRISPR Therapeutics Limited, CRISPR Therapeutics, Inc., and TRACR Hematology Ltd., dated as of April 16, 2021 (incorporated herein by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q filed on April 27, 2021).

Exhibit 10.4 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. AMENDED AND RESTATED Joint Development and Commercialization AGREEMENT BETWEEN vertex pharmaceuticals incorporated VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CriSpr THERAPEUTICS AG CRISPR THERAPEUTICS LI

First Amendment to the Strategic Collaboration and License Agreement dated March 17, 2021, between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated (incorporated herein by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on April 27, 2021).

Exhibit 10.3 [***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Amendment No. 1 to the Strategic Collaboration and License Agreement This Amendment No. 1 to the Strategic Collaboration and License Agreement (the ?Amendment?) is entered into as of March 17, 2021 (?Amen

First Amendment to Lease dated December 2, 2020, by and between CRISPR Therapeutics, Inc. and CRP/KING 33 NY AVE. OWNER, L.L.C. (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on April 27, 2021).

Exhibit 10.2 33 New York Avenue Framingham, Massachusetts 01701 (the ?Building?) FIRST AMENDMENT EXECUTION DATE: December 2, 2020 LANDLORD: CRP/KING 33 NY AVE. OWNER, L.L.C., a Delaware limited liability company TENANT: CRISPR THERAPEUTICS, INC., a Delaware corporation PREMISES: Areas on the first (1st) floor of the Building, the Generator Area, the Loading Dock Premises, and the roof of the Build

Lease, dated May 5, 2020, by and between CRISPR Therapeutics, Inc. and CRP/KING 33 NY AVE. OWNER, L.L.C. (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on April 27, 2021).

Exhibit 10.1 33 NEW YORK AVENUE FRAMINGHAM, MASSACHUSETTS 01701 LEASE SUMMARY SHEET Execution Date: May 5, 2020 Tenant: CRISPR THERAPEUTICS, INC., a Delaware corporation Tenant?s Mailing Address: 610 Main Street Cambridge, MA 02139 Attention: General Counsel Landlord: CRP/KING 33 NY AVE. OWNER, L.L.C., a Delaware limited liability company Building: 33 New York Avenue, Framingham, Massachusetts 017

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi

Quarterly Report - 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEU

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commi

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia - Under terms of amended agreement, Vertex to lead worldwide development, m

Exhibit 99.1 Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001? in Sickle Cell Disease and Beta Thalassemia - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CR

- PRE 14A

PRE 14A 1 crsp-pre14a20210610.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization CRISPR Therapeutics, Inc. Delaware CRISPR Therapeutics Ltd. United Kingdom TRACR Hematology Ltd United Kingdom CTX Financing GmbH Switzerland CTX Securities Corporation Massachusetts Casebia Therapeutics Limited Liability Partnership United Kingdom Casebia Therapeutics LLC Delaware

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 - - The first patient treated in the CLIMB-Thal-111 trial completed two years of follow-up and has enrolled in the l

SCHEDULE 13G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* CRI

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) Vers

Description of Capital Shares

EX-4.1 3 crsp-ex4117.htm EX-4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 16, 2021, CRISPR Therapeutics AG has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our common shares is a summary and

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Amended and Restated Articles of Association of CRISPR Therapeutics AG, dated January 27, 2021.

EX-3.1 2 crsp-ex319.htm EX-3.1 Exhibit 3.1 Articles of association of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I. Corporate Name, Principal Office, Duration and Purpo

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37923 CRISPR THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* CRISPR Therapeutics AG (Name of Issuer) Common stock (Title of Class of Securities) (CUSIP Number) Decembe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CRISPR Therapeutics AG

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CRISPR Therapeutics AG (Name of Issuer) Common Shares, CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES OFFERED MAXIMUM AMOUNT TO BE REGISTERED AMOUNT OF REGISTRATION FEE Common Shares, CHF 0.03 per share $600,000,000 $65,460(1)

424B5 1 d54202d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-227427 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES OFFERED MAXIMUM AMOUNT TO BE REGISTERED AMOUNT OF REGISTRATION FEE Common Shares, CHF 0.03 per share $600,000,000 $65,460(1) (1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Se

Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES OFFERED MAXIMUM AMOUNT TO BE REGISTERED AMOUNT OF REGISTRATION FEE Common Shares, CHF 0.03 per share $350,000,000 $38,185(1)

424B5 Table of Contents CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES OFFERED MAXIMUM AMOUNT TO BE REGISTERED AMOUNT OF REGISTRATION FEE Common Shares, CHF 0.

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

Studies in Patients With Transfusion-dependent β-Thalassemia (TDT) and Sickle Cell Disease (SCD) Are Ongoing Target enrollment 45 patients aged 12 to 35 years with TDT, including β0 / β0 genotypes, defined as a history of at least 100 mL/kg/year or 1

Safety and Efficacy of CTX001™ in Patients With Transfusion-Dependent β-Thalassemia or Sickle Cell Disease: Early Results From the CLIMB THAL-111 and CLIMB SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells Haydar Frangoul, Yael Bobruff, Maria Domenica Cappellini, Selim Corbacioglu, Christine Marie Fernandez, Josu de la Fuente, Stephan Grupp, Rupert Handgretinger, Tony W.

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine - Beta tha

Exhibit 99.1 CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine - Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion - - Sickle cell disease:

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition

Exhibit 99.1 CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, November 4, 2020 - CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ong

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results -Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell ma

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results -Reported positive top-line results from the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies- - Received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for CTX001™ for sickle cell di

Quarterly Report - 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THER

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies -50% (2/4) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; both responder

Exhibit 99.1 CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies -50% (2/4) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; both responders remain in CR- -Early evidence of dose-dependent responses with CTX110- -Acceptable safety profile at DL3 or below- -Management to host

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations

Top-Line Results from the Phase 1 CARBON Trial of CTX110™ October 21, 2020 ® Exhibit 99.

CRSP / CRISPR Therapeutics AG / ARK Investment Management LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.

CRSP / CRISPR Therapeutics AG / Versant Venture Capital IV, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d16950dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities)

CRSP / CRISPR Therapeutics AG / Capital International Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) August 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

CRSP / CRISPR Therapeutics AG / Capital International Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CRISPR Therapeutics AG (Name of Issuer) Common Stock (Title of Class of Securities) H17182108 (CUSIP Number) August 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

Lease, dated July 24, 2020, by and between CRISPR Therapeutics, Inc. and 105 W First Street Owner, L.L.C. (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on July 27, 2020).

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results -Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S.

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results -Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)- -Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN)

Quarterly Report - 10-Q

SS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37923 CRISPR THERAPEUT

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis

(File No. 333-240120

As filed with the Securities and Exchange Commission on July 27, 2020 Registration No.

CRSP / CRISPR Therapeutics AG / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, Par Value CHF 0.03 (Title of Class of Securities) H17182108 (CUSIP Numb

Underwriting Agreement, dated as of June 30, 2020, among CRISPR Therapeutics AG and Goldman Sachs & Co. LLC, BofA Securities, Inc. and Jefferies LLC, as representatives of the underwriters named therein

EX-1.1 Exhibit 1.1 Execution Version CRISPR THERAPEUTICS AG 6,428,572 Common Shares (nominal value CHF 0.03 per share) Underwriting Agreement New York, New York June 30, 2020 Goldman Sachs & Co. LLC BofA Securities, Inc. Jefferies LLC As Representatives of the several Underwriters, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o BofA Securities, Inc. One Bryant Park, 11th

CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

EX-99.2 Exhibit 99.2 CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES ZUG, Switzerland and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares

CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

EX-99.1 Exhibit 99.1 CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES ZUG, Switzerland and CAMBRIDGE, Mass., June 29, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $325,000,000 of com

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 CRISPR THERAPEUTICS AG (Exact Name of Company as Specified in Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission Fi

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee(2) Common shares, CHF 0

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-227427 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee(2) Common shares, CHF 0.03 nominal value 7,392,857 $70.00 $517,499,990 $67,171.50 (1) In

Subject to Completion Preliminary Prospectus Supplement dated June 29, 2020

424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.

Amended and Restated Articles of Association (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 12, 2020).

Exhibit 3.1 Articles of association of CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) with registered office in Zug (Translation; in case of controversy the German text shall prevail) STATUTEN der CRISPR Therapeutics AG (CRISPR Therapeutics SA) (CRISPR Therapeutics Ltd) mit Sitz in Zug I.Corporate Name, Principal Office, Duration and Purpose of the Company I.Firma, Sitz,

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 CRISPR THERAPEUTICS AG (Exact name of Registrant as Specified in Its Charter) Switzerland 001-37923 Not Applicable (State or Other Jurisdiction of Incorporation) (Commis